ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 148 filers reported holding ARCUS BIOSCIENCES INC in Q4 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,222,413 | -18.8% | 68,101 | -8.2% | 0.00% | -50.0% |
Q2 2023 | $1,506,251 | -12.2% | 74,163 | -21.2% | 0.00% | 0.0% |
Q1 2023 | $1,715,764 | +26.4% | 94,066 | +43.3% | 0.00% | 0.0% |
Q4 2022 | $1,357,911 | +193.9% | 65,663 | +271.8% | 0.00% | +100.0% |
Q3 2022 | $462,000 | +15.8% | 17,660 | +12.0% | 0.00% | – |
Q2 2022 | $399,000 | -4.3% | 15,762 | -8.5% | 0.00% | – |
Q1 2022 | $417,000 | +50.5% | 17,231 | +151.7% | 0.00% | – |
Q4 2021 | $277,000 | +9.1% | 6,847 | -6.0% | 0.00% | – |
Q3 2021 | $254,000 | -86.9% | 7,283 | -89.7% | 0.00% | -100.0% |
Q2 2021 | $1,946,000 | -95.5% | 70,860 | -95.4% | 0.00% | -95.5% |
Q1 2021 | $42,972,000 | +46.2% | 1,530,348 | +35.1% | 0.04% | +33.3% |
Q4 2020 | $29,402,000 | +44.3% | 1,132,562 | -4.7% | 0.03% | +26.9% |
Q3 2020 | $20,372,000 | -7.7% | 1,188,559 | +33.2% | 0.03% | -13.3% |
Q2 2020 | $22,083,000 | +16379.9% | 892,604 | +9109.7% | 0.03% | – |
Q1 2020 | $134,000 | +226.8% | 9,692 | +115.8% | 0.00% | – |
Q3 2019 | $41,000 | – | 4,491 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |